Director/PDMR Shareholding

RNS Number : 2195Q

Oxford Biomedica PLC

25 February 2016

 

Director Dealings / Market Share Purchase

Oxford, UK - 25 February 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, today acquired ordinary shares in the Group as set out below, under the market share purchase agreement outlined in the announcement on 15 December 2015 of his appointment.

Under the market share purchase agreement one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price. This purchase represents the first monthly purchase of shares since Dr Tallarigo's appointment as Chairman on 1 February 2016.

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired	Number of Ordinary Shares	% of total issued share capital
Dr Lorenzo Tallarigo	Chairman	6.51p	36,370	36,370	0.001%

The issued share capital of the Group is 2,702,853,244 ordinary 1p shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes to editors

Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector^® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of six gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

RDSBRGDDLBDBGLU